BioSpace News Archive

Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tomography (PET) study, confirming high levels of Xanamem target occupancy in the brain at safe, well tolerated, and biologically active doses, has been published in the Journal of Alzheimer’s Disease.

Diabetes mellitus and sarcopenia pose a substantial challenge to public health, especially among the elderly.

ReAlta Life Sciences, Inc. today announced the appointment of two experienced R&D leaders, John Baldoni, PhD and Eric Van Gieson, PhD to its Board of Directors, effective immediately.

LANGaware, an innovative leader in digital cognitive and behavioral health diagnostics, is announcing that it will partner with Premier’s (NASDAQ: PINC) PINC AI™ Applied Sciences (PAS) to leverage Real-World Data (RWD) for the development of novel therapeutics addressing neurodegenerative and behavioral health diseases.

Petros Pharmaceuticals, Inc. announces it has scheduled two meetings with the U.S. Food and Drug Administration (FDA) to review the Company’s progress and path forward in developing STENDRA as the first PDE-5 inhibitor approved as an over-the-counter medication for erectile dysfunction.

Medicines360, a global nonprofit pharmaceutical organization specializing in women’s health, announced the appointment of Lisa David as Chair of the Board of Directors, effective January 1, 2024.

PharmAla Biotech Holdings Inc. is excited to announce its new OTC ticker, “MDXXF”, which will go into effect on January 24th.

Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the closing of an $8.3 Million Series A investment round.

VGXI, Inc. have entered a strategic multi-year partnership.

OrphAI Therapeutics Inc. announced the appointment of Jay S. Fine, Ph.D. to its Board of Directors.